Breast Cancer Research and Treatment

, Volume 115, Issue 2, pp 373–380 | Cite as

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

  • Rupert Bartsch
  • Brigitte Mlineritsch
  • Michael Gnant
  • Thomas Niernberger
  • Ursula Pluschnig
  • Richard Greil
  • Catharina Wenzel
  • Paul Sevelda
  • Josef Thaler
  • Margaretha Rudas
  • Michael Pober
  • Christoph C. Zielinski
  • Guenther G. Steger
  • on behalf of the Austrian Fulvestrant Registry
Clinical Trial


Background Endocrine therapy is the preferred treatment in oestrogen- and/or progesterone-receptor (ER/PgR) positive breast cancer. Fulvestrant is a pure ER-antagonist. We present results from the Austrian Fulvestrant Registry. Methods Three-hundred and fifty patients were included. Time to progression (TTP) was defined as primary endpoint. A multivariate analysis was performed to identify factors significantly associated with TTP. Results Fulvestrant was administered as first-line therapy in 26%, second-line in 49%, and third-line or beyond in 25%. TTP was median 7 months. We observed a response in 15% of patients and 41% had SD ≥ 6 months. First-line treatment and non-visceral metastases were associated with longer TTP. One case of pulmonary embolism was reported. Grade 3 toxicities consisted of joint pain (1.4%), nausea (1.4%) and hot flashes (0.3%). Conclusions Fulvestrant was effective and well tolerated. TTP was superior to other trials, due to the large proportion of first-line patients. Activity is apparently independent of Her2-status.


Endocrine treatment Fulvestrant Metastatic breast cancer Oestrogen-receptor 



Apart from the authors of this manuscript, individuals contributing to the Austrian Fulvestrant Registry included the following: Aiginger P, Andel J, Artner S, Fiegl M, Fortelny A, Gunegger D, Gomar-Hoess C, Halbritter W, Haslbauer F, Hehenwarter W, Hellan J, Hojas S, Horvath W, Kier P, Kis A, Kopetzky G, Kretschmar A, Kührer I, Labuda B, Lass H, Lobmaier G, Loncsar G, Luschin-Ebengreuth G, Magg P, Manfreda D, Medl M, Niedermayer A, Papala T, Paurits T, Rainer G, Reimer D, Renner K, Riedl M, Schenk T, Schmid G, Stangl W, Tichatschek R, Thiel I, Trapl H, Ulsperger E, Urbania A, Walla B, Wette V, Wilthoner K. The Austrian Fulvestrant Registry was supported by a grant from AstraZeneca Pharmaceuticals.


  1. 1.
    O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(3):20–29. doi: 10.1634/theoncologist.10-90003-20 PubMedCrossRefGoogle Scholar
  2. 2.
    Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618. doi: 10.1056/NEJM199811263392207 PubMedCrossRefGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0 CrossRefGoogle Scholar
  4. 4.
    Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398. doi: 10.1093/annonc/mdg362 PubMedCrossRefGoogle Scholar
  5. 5.
    Bajetta E, Procopio G, Ferrari L et al (2002) A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 94:299–304. doi: 10.1002/cncr.10239 PubMedCrossRefGoogle Scholar
  6. 6.
    Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma. Cancer 92:2247–2258. doi:10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-YPubMedCrossRefGoogle Scholar
  7. 7.
    Dutertre M, Smith CL (2000) Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295:431–437PubMedGoogle Scholar
  8. 8.
    Schiff R, Massarweh SA, Shou J et al (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10(1 Pt 2):331–336. doi: 10.1158/1078-0432.CCR-031212 CrossRefGoogle Scholar
  9. 9.
    Sun M, Paciga JE, Feldman RI et al (2001) Phosphatidylinostol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (Erα) via interaction between Erα and PI3K. Cancer Res 61:5985–5991PubMedGoogle Scholar
  10. 10.
    Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442. doi: 10.1056/NEJMra023246 PubMedCrossRefGoogle Scholar
  11. 11.
    Miller WR, Bartlett JM, Canney P et al (2007) Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 103:149–160. doi: 10.1007/s10549-006-9369-7 PubMedCrossRefGoogle Scholar
  12. 12.
    Macedo LF, Sabnis G, Brodie A (2008) Preclinical modeling of endocrine response and resistance. Cancer 112(Suppl 3):679S–688S. doi: 10.1002/cncr.23191 CrossRefGoogle Scholar
  13. 13.
    Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873PubMedGoogle Scholar
  14. 14.
    Fawell SE, White R, Hoare S et al (1990) Inhibition of estrogen receptor-DNA binding by the “pure” anti-estrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883–6888. doi: 10.1073/pnas.87.17.6883 PubMedCrossRefGoogle Scholar
  15. 15.
    Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7:17–28. doi: 10.1677/erc.0.0070017 PubMedCrossRefGoogle Scholar
  16. 16.
    Howell A (2006) Is fulvestrant (“faslodex”) just another selective estrogen receptor modulator? Int J Gynecol Cancer 16(Suppl 2):521S–523S. doi: 10.1111/j.1525-1438.2006.00686.x CrossRefGoogle Scholar
  17. 17.
    Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways is a cause for endocrine resistance in breast cancer. Clin Cancer Res 11(2 Pt 2):865–870Google Scholar
  18. 18.
    Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721–747. doi: 10.1677/erc.1.00857 PubMedCrossRefGoogle Scholar
  19. 19.
    Bartsch R, Wenzel C, Altorjai G et al (2007) Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 13:4435–4439. doi: 10.1158/1078-0432.CCR-06-3050 PubMedCrossRefGoogle Scholar
  20. 20.
    Robertson JF, Steger GG, Neven P et al (2007) Fulvestrant in the treatment of Her2-positive advanced breast cancer (ABC). J Clin Oncol 25(Suppl 18):47S. doi: 10.1200/JCO.2006.09.3146 Google Scholar
  21. 21.
    Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20:3396–3403. doi: 10.1200/JCO.2002.10.057 PubMedCrossRefGoogle Scholar
  22. 22.
    Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:386–3395. doi: 10.1200/JCO.2002.10.058 CrossRefGoogle Scholar
  23. 23.
    Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women—a prospective combined analysis of two multicenter trials. Cancer 98:229–238. doi: 10.1002/cncr.11468 PubMedCrossRefGoogle Scholar
  24. 24.
    Steger GG, Bartsch R, Wenzel C et al (2005) Fulvestrant (“Faslodex”) in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41:2655–2661PubMedCrossRefGoogle Scholar
  25. 25.
    Steger GG, Gips M, Simon SD et al (2005) Fulvestrant (“Faslodex”): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31(Suppl 2):10S–16S. doi: 10.1016/j.ctrv.2005.08.009 CrossRefGoogle Scholar
  26. 26.
    Mlineritsch B, Psenak O, Mayer P et al (2007) Fulvestrant („faslodex”) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the Compassionate Use Programme. Breast Cancer Res Treat 106:105–112. doi: 10.1007/s10549-006-9482-7 PubMedCrossRefGoogle Scholar
  27. 27.
    Chia S, Gradisher W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromtase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664–1670. doi: 10.1200/JCO.2007.13.5822 PubMedCrossRefGoogle Scholar
  28. 28.
    Neven P, Paridaens R, Pelgrims G et al (2008) Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 109:59–65. doi: 10.1007/s10549-007-9628-2 PubMedCrossRefGoogle Scholar
  29. 29.
    Vergote I, Robertson JFR, Kleeberg U et al (2003) Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79:207–211. doi: 10.1023/A:1023983032625 PubMedCrossRefGoogle Scholar
  30. 30.
    Howell A (2002) Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 76(Suppl 1):72SGoogle Scholar
  31. 31.
    Perey L, Paridaens R, Hawle H et al (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18:64–69. doi: 10.1093/annonc/mdl341 PubMedCrossRefGoogle Scholar
  32. 32.
    Beslija S, Bonneterre J, Burstein H et al (2007) Second consenus on medical treatment of metastatic breast cancer. Ann Oncol 18:215–225. doi: 10.1093/annonc/mdl155 PubMedCrossRefGoogle Scholar
  33. 33.
    Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMedCrossRefGoogle Scholar
  34. 34.
    Stendhal M, Ryden L, Nordenskjold B et al (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614–4618. doi: 10.1158/1078-0432.CCR-06-0248 CrossRefGoogle Scholar
  35. 35.
    Ellis MJ, Coop A, Singh B et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523–6531PubMedGoogle Scholar
  36. 36.
    Nicholson RI, McClelland RA, Robertson JF et al (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373–387. doi: 10.1677/erc.0.0060373 PubMedCrossRefGoogle Scholar
  37. 37.
    Osborne CK, Schiff R, Fuqua SA et al (2001) Estrogen receptor: current understandings of its activation and modulation. Clin Cancer Res 7(Suppl 12):4338S–4342SPubMedGoogle Scholar
  38. 38.
    Howell A, Robertson JFR, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605–1613. doi: 10.1200/JCO.2004.02.112 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Rupert Bartsch
    • 1
  • Brigitte Mlineritsch
    • 2
  • Michael Gnant
    • 3
  • Thomas Niernberger
    • 4
  • Ursula Pluschnig
    • 1
  • Richard Greil
    • 2
  • Catharina Wenzel
    • 1
  • Paul Sevelda
    • 5
  • Josef Thaler
    • 6
  • Margaretha Rudas
    • 7
  • Michael Pober
    • 8
  • Christoph C. Zielinski
    • 1
  • Guenther G. Steger
    • 1
  • on behalf of the Austrian Fulvestrant Registry
    • 9
  1. 1.First Department of Medicine and Cancer Centre, Clinical Division of OncologyMedical University of ViennaViennaAustria
  2. 2.Paracelsus Private Medical UniversitySalzburgAustria
  3. 3.Department of SurgeryMedical University of ViennaViennaAustria
  4. 4.Department of SurgeryLKH LeobenLeobenAustria
  5. 5.Department of GynaecologyKH HietzingViennaAustria
  6. 6.Department of Medicine 4KH Wels and GrieskirchenWelsAustria
  7. 7.Department of PathologyMedical University of ViennaViennaAustria
  8. 8.Department of MedicineKH St. PoeltenSt. PoeltenAustria
  9. 9.ViennaAustria

Personalised recommendations